Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Challenges in Antiviral Therapy for Hepatitis C

    Contains 2 Component(s) Recorded On: 07/23/2019

    Webinar hosted by the Hepatitis C Special Interest Group on July 23, 2019.

    Management of HCV after therapy has complexity if patients continue to engage in high risk activities, are at risk for advanced liver disease progression or have failed first line therapy. In addition, these complexities are especially important to consider as HCV therapy moves outside of subspecialty care. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Stuart C. Gordon

    Dr. Gordon is a Professor of Medicine at Wayne State University School of Medicine and Director, Division of Hepatology, at Henry Ford Hospital. He received his training in clinical hepatology at the University of Miami, under Drs. Leon and Eugene Schiff. His major research interest is in the epidemiology and treatment of viral hepatitis. He has authored or coauthored over 200 papers, reviews and chapters, serves on several NIH Study Sections, and serves on the editorial board of Clinical Gastroenterology and Hepatology. Dr. Gordon is currently an appointed member of the AASLD-IDSA Hepatitis C Guidance Committee.

    In collaboration with the Centers for Disease Control, Dr. Gordon is the Principal Investigator of the multicenter CHeCS (Chronic Hepatitis Cohort Study) that examines the health burden, natural history, epidemiology and treatment challenges posed by chronic viral hepatitis in the United States. He also serves as Principal Investigator of the Fibrotic Liver Disease (FOLD) consortium of 11 US medical centers that collectively serve 4.2 million patients, and which examines the prevalence, natural history, treatment uptake/response, and clinical outcomes of patients with Primary Biliary Cholangitis (PBC) in the United States.

    Joseph Lim

    Dr. Lim is a Professor of Medicine in the Section of Digestive Diseases at Yale University, where he serves as Director of the Yale Viral Hepatitis Program. He is a graduate of the Feinberg School of Medicine at Northwestern University (Chicago, Illinois, USA), and completed training in Internal Medicine at Yale University (New Haven, Connecticut, USA), and Gastroenterology and Hepatology at Stanford University (Palo Alto, California, USA).

    In his role at the Yale Liver Center, he directs an active clinical trials program evaluating novel investigational agents for hepatitis B, hepatitis C, and NASH. He serves on the national EPIC Gastroenterology Specialty Steering Board, the steering committee of HCV-TARGET, and on the AASLD HCV SIG Steering Committee.

    Brian Pearlman

    Brian L. Pearlman, MD is Medical Director for Wellstar Atlanta Medical Center’s Center for Hepatitis C in Atlanta Georgia. He is also Professor of Medicine at the Medical College of Georgia and Professor of Medicine at Emory School of Medicine. Dr. Pearlman completed his medical degree at the University of Miami, Florida and his post-graduate training included both Diagnostic Radiology at University of Texas-Southwestern and Internal Medicine at Baylor University-Dallas, Texas.

    Dr. Pearlman is Faculty for the American College of Physicians (FACP) , Fellow of the American Association for the Study of Liver Diseases (FAASLD), and members of the American Academy of HIV Medicine, and the American Gastroenterological Association. He sat on the Board of Directors for The American Liver Foundation’s Southeast Chapter.

    Dr. Pearlman is widely published in leading journals such as The Lancet, Gastroenterology, HEPATOLOGY, The American Journal of Gastroenterology, The Lancet Infectious Disease, Clinical Infectious Diseases and The American Journal of Medicine. Dr. Pearlman is active in both patient care and in teaching physicians. He has been the recipient of numerous teaching awards, and also an active investigator in multiple hepatitis C-related trials, some of which are in collaboration with the CDC’s Division of Viral Hepatitis.

    Nancy Reau (Moderator)

    Dr. Nancy Reau is currently Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center. Dr Reau’s research interest is in viral hepatitis drug development as well as utilization. She has authored or co-authored more than 100 peer-reviewed articles, invited reviews, editorials and online programs, as well as several book chapters, and two books. She is the editor-in-chief for Clinical Liver Disease, the AASLD multimedia journal. She was one of the original authors of the AASLD/IDSA hepatitis C guidance document.

    She is currently a member of the steering committee for the Hepatitis C Special Interest Group for the AASLD and is a member of the gastroenterology writing committee for the American Board of Internal Medicine.

  • Evaluation of Renal Dysfunction and Hyponatremia in Patients with Cirrhosis

    Contains 2 Component(s) Recorded On: 07/09/2019

    Webinar hosted by the Clinical Practice Special Interest Group on July 9, 2019.

    This webinar will discuss the management of renal insufficiency in patients with cirrhosis, in both the inpatient and outpatient settings. Topics to be discussed include workup of the patient with acute kidney injury in the outpatient setting, management of diuretics and evaluation using novel biomarkers. The audience member will be able to understand how to balance diuretics usage to account for symptom control versus patient safety, recognize the spectrum of etiologies of kidney dysfunction in the patient with cirrhosis and how to evaluate for them, and treatment of renal failure in the inpatient setting.  We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Josh Levitsky

    Josh Levitsky, MD, MS is currently a Professor of Medicine and Surgery in the Division of Gastroenterology & Hepatology at the Northwestern University Feinberg School of Medicine. Dr. Levitsky received his B.S. from the University of Michigan and M.D. from the Albert Einstein College of Medicine. He then completed an Internal Medicine residency and Gastroenterology fellowship at the University of Chicago Hospitals and a Transplant Hepatology fellowship at the University of Nebraska Medical Center, receiving an AASLD Fellowship Award. He is currently certified by the American Board of Internal Medicine in Gastroenterology and Transplant Hepatology. At Northwestern, he completed a Master of Science in Clinical Investigation, is the Director of Liver Research, and is the program director for both Gastroenterology and Transplant Hepatology Fellowships. He has been elected to the Northwestern Feinberg Academy of Medical Educators and has received several teaching awards.

    Dr. Levitsky is an active member of several professional societies, including the American Society of Transplantation and International Liver Transplantation Society where he served on the executive boards, as well as the AASLD where he has served on several committees. He is a Deputy Editor for the American Journal of Transplantation and on the Editorial Board for HEPATOLOGY. Dr. Levitsky’s academic interests are clinical and translational in nature, with a focus on liver transplant immunosuppression, tolerance and biomarkers. He previously received an AASLD Career Development Award in Liver Transplantation and has published numerous peer-reviewed journal articles, abstracts, book chapters and reviews on topics relevant to liver disease and transplantation. He is the principal and co-investigator for a number of NIH, pharmaceutical and investigator-initiated trials. His goal is to advance clinical/translational research in immune-mediated liver diseases and liver transplantation, identifying biomarkers and novel strategies to optimize outcomes.

    Vinay Sundaram (Moderator)

    Dr. Vinay Sundaram is a transplant hepatologist at Cedars-Sinai Medical Center, where he serves as assistant medical director of liver transplantation and director of hepatology outcomes research. He has been a member of the AASLD since 2009. He is actively involved with numerous committees including the AASLD membership and mentorship committee, chair of the education subcommittee for the clinical practice special interest group.  In addition, he is on the membership and professional standards committee for UNOS. His research interests include end-stage liver disease, acute on chronic liver failure and post-transplant outcomes. He has over 100 published manuscripts and abstracts and is on the editorial board for Hepatology Communications. 

  • Clinical Hepatology Update On-Demand 2019

    Contains 37 Component(s), Includes Credits Recorded On: 06/14/2019

    Claim CME for the 2019 AASLD Clinical Hepatology Update.

    The Clinical Hepatology Update conference is designed for all medical professionals who manage care for patients with liver disease, including nurse practitioners, physician assistants, RNs, primary care physicians, medical students and GI or hepatology trainees. The conference will provide an update and review of the evolving practices in the clinical management of liver diseases.

    Core Competencies:  Patient Care and Procedural Skills Provide Patient-centered Care Values/Ethics for Interprofessional Practice Medical Knowledge Work in Interdisciplinary Teams Roles/Responsibilities Practice-based Learning and Improvement Employ Evidence-based Practice Interprofessional Communication Interpersonal and Communication Skills Apply Quality Improvement Teams and Teamwork Systems-based Practice

    Program Chairs:  Marcelo Kugelmas, MD, FAASLD Elizabeth K. Goacher, PA-C, MHS Janice Jou, MD, MHS  Lisa Catalli, MSN, NP-B

    CME Hours: 13.00 AMA PRA Category 1 Credits

    MOC Points: 13.00 MOC Points 

    Continuing Education (Nursing Credits): 13.00 Contact Hours

    Pharmacology: 1.25 Pharmacology Credits 

    All sessions must be viewed and all post-tests must be completed successfully to earn credits or points for this activity. Please note, no partial credits or points will be given.  

    Release Date: July 31, 2019
    Expiration Date: July 30, 2021


    Copyright: All faculty in this activity have given their permission for publication OR ©2019 AASLD

    Upon completion of this activity, learners will be able to: 

    To understand and describe the current standard of care for the diagnosis and management of non-alcoholic fatty liver disease.
    Manage patients with complications of portal hypertension.
    Recognize when decompensated cirrhosis patients are appropriate candidates for palliative care and hospice referral.

    Hepatologists
    Gastroenterologists
    Nurses
    Nurse Practitioners
    Physician Assistants
    Transplant Coordinators
    Fellows/Trainees 

    Jasmohan Bajaj, MD, FAASLD
    Bryan Balmadrid, MD
    Stephen Caldwell, MD, FAASLD
    Lisa Catalli, MSN, NP-BC
    Michael Chang, MD, MSc, MBA, FAASLD
    Kathleen Corey, MD, MPH, MMSc
    Khashayar Farsad, MD
    Jaquelyn Fleckenstein, MD, FAASLD
    Catherine Frenette, MD
    Richard Gilroy, MD
    Robert Gish, MD, FAASLD
    Elizabeth Goacher, PA-C, MHS
    Janice Jou, MD, MHS
    Marcelo Kugelmas, MD, FAASLD
    Jennifer Lai, MD
    Anne Larson, MD, FAASLD
    Michael Leise, MD
    Cynthia Levy, MD, FAASLD
    Willscott Naugler, MD, FAASLD
    Jody Olson, MD
    Arpan Patel, MD
    Sonali Paul, MD
    K Rajender Reddy, MD, FAASLD
    Puneeta Tandon, MD, FRCPC
    Elliot Tapper, MD
    Robert Weinrieb, MD

    Disclosures

    This enduring educational activity has been planned in accordance with AASLD and ACCME Standards of Commercial Support by members of the Clinical Hepatology Update faculty and the Clinical Research Committee and Governing Board.

    As an accredited provider, AASLD requires individuals involved in the planning of continuing medical education (CME) activities to disclose all financial relationships, including those of their spouse or partner, with a commercial interest within the past 12 months. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. All conflicts of interest are resolved prior to participation.

    Faculty Disclosures
    Jasmohan Bajaj, MD, FAASLD       
    Advisory Board and/or Committee and Review Panels: Valeant, Norgine, Intercept
    Honoraria for CME Activities: Integrity CE. CLD communications
    Grants/Research Support: Valeant 

    Bryan Balmadrid, MD          
    Nothing to disclose

    Stephen Caldwell, MD, FAASLD    
    Grant/Research Support: Genfit, TaiwanJ, Immuron, Gilead Sciences, Immuron, NGM, Mallinckrodt, Conatus, Galmed, Vital Therapy

    Lisa Catalli, MSN, NP-BC    
    Nothing to disclose 

    Michael Chang, MD, MSc, MBA, FAASLD 
    Nothing to disclose 

    Kathleen Corey, MD, MPH, MMSc  
    Speaking and Teaching: Synageva
    Scientific Consulting: Novo Nordisk

    Khashayar Farsad, MD        
    Scientific Consulting: Cook Medical, Neuwave Medical 
    Grants/Research Support: Guerbet, LLC Leadership in related society: American Society of Digestive Disease Interventions (consensus panel committee) 

    Jaquelyn Fleckenstein, MD, FAASLD       
    Nothing to disclose

    Catherine Frenette, MD       
    Scientific Consulting: Bayer, Intercept; Speakers Bureau: Bayer, Gilead

    Richard Gilroy, MD  
    Speakers Bureau: Novartis, Gilead, Salix

    Robert Gish, MD, FAASLD  
    Scientific Consulting: Abbot, AbbVie, Alexion, Arrowhead, Bayer AG, Bristol-Myers Squibb Company, Contravir, Eiger, Enyo, eStudySite, Genentech, Gilead Sciences, HepaTX, HepQuant, Hoffmann-LaRoche Ltd., Intellia, Intercept, Ionis Pharmaceuticals, Janssen, MedImmune, Merck, Shionogi, Transgene
    Trimaran Leadership in related society: AbbVie, Merck, Arrowhead, Bayer, Contravir, Dova Pharmaceuticals, Eiger, Enyo, Janssen, Medimmune, Janssen/J&J, Intercept, Shionogi, Spring Bank, Ionis
    Speakers Bureau: Alexion, Bayer, BMS, Dova, Gilead Sciences Inc., AbbVie, Merck

    Elizabeth Goacher, PA-C, MHS      
    Scientific Consulting: Gilead Pharmaceuticals, AbbVie Pharmaceuticals
    Speakers Bureau: AbbVie Pharmaceticals, Gilead Pharmaceuticals

    Janice Jou, MD, MHS          
    Nothing to disclose

    Marcelo Kugelmas, MD, FAASLD  
    Speakers Bureau: Intercept, Dova, Merck, Gilead, Abbvie, Salix
    Scientific Consulting: Gilead, Abbvie, Merck, Salix, Shinogi, Dova, Intercept, Mallinkrodt 
    Grants/Research Support: Novartis, Enanta, Tobira, Pfizer, Madrigal, Genfit, Shire, Cirius, Intercept, Dova, Gilead

    Jennifer Lai, MD       
    Scientific Consulting: Third Rock Ventures, LLC, Axcella

    Anne Larson, MD, FAASLD
    Nothing to disclose

    Michael Leise, MD    
    Nothing to disclose

    Cynthia Levy, MD, FAASLD
    Grants/Research Support: Intercept, Gilead, GSK, Novartis, Genfit, CymaBay, Enanta, Arena, Durect, High Tide, Eli Lilly
    Scientific Consulting: Target Pharma Solutions, Pliant, Cara Therapeutics
    Leadership in related society: Associate Editor- Liver Transplantation

    Willscott Naugler, MD, FAASLD     
    Nothing to disclose 

    Jody Olson, MD       
    Nothing to disclose 

    Arpan Patel, MD       
    Nothing to disclose

    Sonali Paul, MD        
    Nothing to disclose 

    K Rajender Reddy, MD, FAASLD   
    Grant/Research Support: AbbVie,Gilead, Janssen, Merck, Intercept, Mallinckrodt, Conatus, Novartis 

    Puneeta Tandon, MD, FRCPC        
    Advisory Committee and/or Review Panels: Lupin Pharma Canada 

    Elliot Tapper, MD     
    Grants/Research Support: Valeant, Gilead
    Scientific Consulting: Novartis

    Robert Weinrieb, MD           
    Nothing to disclose

    Planning Committee Disclosures
    Curtis K. Argo, MD, MS, FAASLD (Maintenance of Certification Committee)
    Nothing to disclose 

    Meena B. Bansal, MD, FAASLD (Governing Board)
    Nothing to disclose 

    Jorge A. Bezerra, MD, FAASLD (Governing Board)
    Grant/Research Support: Shyer, Gilead 

    Mamatha Bhat (Clinical Research Committee)
    Nothing to disclose 

    Therese Bittermann, MD (Clinical Research Committee)
    Nothing to disclose

    Kenneth D. Chavin, MD, PhD (Clinical Research Committee)
    Nothing to disclose

    Raymond Chung, MD, FAASLD (Governing Board; Maintenance of Certification Committee)
    Grant/Research Support: AbbVie, BMS, Merck, Boehringer Ingelheim, Gilead, Janssen
    Other: DSMB – Alnylam

    Laurie DeLeve, MD, PhD, FAASLD (Governing Board) 
    Consulting: Daiichi Sankyo; Seagen; Pfizer

    Edward Doo, MD (Clinical Research Committee) 
    Nothing to disclose

    Robert J. Fontana, MD, FAASLD (Clinical Research Committee)
    Grants/Research Support: BMS, Gilead, Abbvie
    Consulting: Sanofi

    Kimberly A Forde, MD, MHS (Clinical Research Committee)
    Nothing to disclose 

    Michael W. Fried, MD, FAASLD (Governing Board)
    Stock/Stock Options: TARGET PharmaSolutions Consulting: AbbVie, BMS, Merck, TARGET PharmaSolutions (All uncompensated)
    Grant/Research Support: AbbVie, BMS, Gilead, Merck, National Institutes of Health

    Debra Guss, DNP, RN, ANP-C (Maintenance of Certification Committee)
    Nothing to disclose

    Steven K. Herrine, MD, FAASLD (Maintenance of Certification Committee)
    Grant/Research Support: Gilead, BMS, Galectin, Intercept

    Vandana Khungar, MD, MSc (Maintenance of Certification Committee)
    Nothing to disclose

    Ayman A. Koteish, MD, FAASLD (Maintenance of Certification Committee)
    Nothing to disclose

    Paul Yien Kwo, MD, FAASLD (Clinical Research Committee) 
    Consulting: Gilead, Abbvie Grants/Research Support: BMS, Abbvie 

    John R. Lake, MD, FAASLD (Governing Board)
    Consulting: Vital Therapies, SRTR
    Other: Intercept DSMB

    Jennifer Cindy Lai, MD (Clinical Research Committee)
    Consulting: Third Rock Ventures, LLC, Axcella

    Rohit Loomba, MD (Clinical Research Committee)
    Grants/Research Support: Allergan, BMS, BI, Daiichi-Sankyo Inc., Galectin, Galmed, GE, Genfit, Gilead, Intercept, Janseen Inc, Madrigal, Merck, NGM, Pfizer, Prometheus, Siemens, Sirius
    Consulting: Bird Rock Bio, Celgene, Enanta, GRI Bio, Madrigal, Metacrine, NGM, Receptos, Sanofi, Arrowhead Research, Galmed, NGM, GIR, Inc. and Metacrine, Inc

    Bruce A. Luxon, MD, PhD, FAASLD (Governing Board)
    Board Membership: ACG Research Committee, Baxalta, DSMB
    Consulting: National Hemophilia Foundation 

    Lopa Mishra, MD, FAASLD (Governing Board)
    Grant/Research Support: NIH 

    Smruti R. Mohanty, MD, MS (Maintenance of Certification Committee)
    Leadership in related society: Education Committee Member, the Alliance for Academic Internal Medicine (AAIM) (July 2016-19) Editorial Board, World Journal of Gastroenterology (2007-Present) Editorial Board, Digestive Disease & Science (2009-Present) Editorial Board, World Journal of Hepatology (2009-Present) Reviewer: Hepatology, Clinical Gastroenterology & Hepatology, Digestive Disease & sciences, Post Graduate Medical Journal, World Journal of Gastroenterology World journal of hepatology
    Speaker's Bureau: Gilead Science, Merck, Abbvie and Intercept 

    David C. Mulligan, MD, FAASLD (Governing Board)
    Nothing to disclose 

    Arpan A. Patel, MD (Clinical Research Committee) 
    Nothing to disclose

    Heather M. Patton, MD, FAASLD (Maintenance of Certification Committee) 
    Grant/Research Support: Gilead Sciences 

    K. Gautham Reddy, MD, FAASLD (Maintenance of Certification Committee) 
    Leadership in related society: Board, Committee, Journal: Member, Training Committee: American College of Gastoneterology
    Speaker's Bureau: Intercept Dova;
    Research Grants: Merck Intercept Genfit 
    Scientific Consulting:  Advisor to Industry Commercial Enterprise, including Development of Educational Presentations: Intercept

    Susan M. Salahshor, PhD, PA-C (Clinical Research Committee)
    Nothing to disclose

    Ronald J. Sokol, MD, FAASLD (Governing Board)
    Consulting: Alexion; Albireo; Retrophin; Shire Grant/Research Support: Lumena/Shire; FFF Enterprises 

    Grace L. Su, MD, FAASLD (Maintenance of Certification Committee)
    Company Employee, Officer, Director: My husband and son have equity interest in Applied Morphomics and Prenovo

    Shikha Sundaram, MD, MSCI (Clinical Research Committee)
    Nothing to disclose

    Ryan M. Taylor, MD (Maintenance of Certification Committee)
    Speaker's Bureau: Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Bristol-Myers Squibb, Merck, Inc., Abbvie, Inc.
    Grant/Research Support: Conatus Pharmaceuticals, Gilead Sciences, Abbvie, Conatus Pharmaceuticals 

    Norah Terrault, MD, MPH, FAASLD (Governing Board; Clinical Research Committee)
    Advisory Committees and/or Review Panels: Dova
    Grant/Research Support: AbbVie, Gilead, BMS, Merck 

    Kymberly Watt, MD (Clinical Research Committee)
    Other (eg. Expert testimony): Intercept - site- PI Gilead - site PI, co-I Conatus - site co-I Novartis - pr subanalysis Pfizer- site co-I all multicenter study related

    Julia J. Wattacheril, MD, MPH (Clinical Research Committee)
    Grants/Research Support: Conatus Pharmaceuticals, Genfit Pharmaceuticals, Galectin Therapeutics, Gilead Sciences, Intercept Pharmaceuticals

    Staff Disclosures
    Dominique Clayton 
    Nothing to disclose

    Katie Duggan
    Nothing to disclose

    Janeil Klett
    Nothing to disclose

    Denise Seise
    Nothing to disclose

    Anne Wrobel 
    Nothing to disclose 

    Amedco Staff Disclosures
    Sheryl Morgan
    Nothing to disclose


    Acknowledgement of Financial or In-Kind Commercial Support

    No financial or in-kind commercial support was received for this educational activity.

    Satisfactory completion 

    Participants must pass a post-test with a score of 70% or higher and complete an evaluation to receive a certificate of completion. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement. All sessions must be viewed and all post-tests must be completed successfully to earn credits or points for this activity. Please note, no partial credits or points will be given.  

    Credits Offered Continuing Medical Education (CME): 13.00 AMA PRA Category 1 Credits™; Maintenance of Certification (MOC): 13.00 MOC Points; Continuing Education (CE): 13.00 Contact Hours; Nurse Pharmacology Credits: 1.25 pharmacotherapeutic Credits..

    Accreditation and Designation Statements

    Continuing Medical Education (CME) The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this live activity for a maximum of 13.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Maintenance of Certification (MOC) Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

    Continuing Education (Nursing Contact Hours)  In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 13.00 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    Nurse Pharmacology Credits  The following presentations are also eligible for 1.25 pharmacotherapeutic hours:

    The Other Side of the Triad: Non-Cirrhotic Portal Hypertension Anticoagulation in Portal Hypertension Back to the Basics: Hepatitis B Management AIH: When to Change and If/When to Stop Therapy

    Please note onsite documentation for identification of sessions eligible for pharmacotherapeutic hours and self-submit those to your board. Keep the agenda as a reference in case they have questions.

    Claiming CME Credits Physicians and other health care professionals seeking 13.00 AMA PRA Category 1 Credits™ for this enduring continuing medical education activity must complete an evaluation by Friday, July 30, 2021

    Claiming ABIM MOC Points Physicians seeking ABIM and or ABP MOC points must complete the CME and MOC evaluation by Friday, July 30, 2021. Requests for MOC after this date will not be honored. The MOC evaluation is included in the CME evaluation.

    MOC Points will be reported to the ABIM and ABP by the end of each month through August 2021 for individuals who successfully complete the MOC evaluation.

    Claiming CE Contact Hours and Pharmacology Credits Nurses seeking a maximum of 13.00 contact hours or Nurses seeking up to 1.25 pharmacotherapeutic credits must complete an evaluation by Friday, July 30, 2021.

  • Clinical Hepatology Update Conference 2019

    Contains 26 Component(s) Recorded On: 06/14/2019

    Addressing Gaps in the Current Guidance: Assessing DILI with Novel Treatments or Preexisting Liver Disease in Clinical Trials

    ** VIEW ONLY CONTENT. The Clinical Hepatology Update 2019 enduring course will be available soon. It will be available under the "On-Demand Accredited Activities". **

    The Clinical Hepatology Update conference is designed for all medical professionals who manage care for patients with liver disease, including nurse practitioners, physician assistants, RNs, primary care physicians, medical students and GI or hepatology trainees. The conference will provide an update and review of the evolving practices in the clinical management of liver diseases.

    Core Competencies:  

    • Patient Care and Procedural Skills
    • Provide Patient-centered Care
    • Values/Ethics for Interprofessional Practice
    • Medical Knowledge
    • Work in Interdisciplinary Teams
    • Roles/Responsibilities
    • Practice-based Learning and Improvement
    • Employ Evidence-based Practice
    • Interprofessional Communication
    • Interpersonal and Communication Skills
    • Apply Quality Improvement
    • Teams and Teamwork
    • Systems-based Practice

    Program Chairs:

    Lisa Catalli, MSN, NP-B
    Elizabeth K. Goacher, PA-C, MHS
    Janice Jou, MD, MHS
    Marcelo Kugelmas, MD, FAASLD



    • To understand and describe the current standard of care for the diagnosis and management of non-alcoholic fatty liver disease.
    • Manage patients with complications of portal hypertension.
    • Recognize when decompensated cirrhosis patients are appropriate candidates for palliative care and hospice referral.  

    • Hepatologists 
    • Gastroenterologists    
    • Nurses
    • Nurse Practitioners    
    • Physician Assistants  
    • Transplant Coordinators
      Fellows/Trainees
  • HCV Treatment in Patients with IDU

    Product not yet rated Contains 2 Component(s) Recorded On: 05/21/2019

    Webinar hosted by the Hepatitis C Special Interest Group on May 21, 2019.

    Injection Drug Use (IDU) remains the leading risk factor for HCV.  Unfortunately, significant obstacles limit every aspect of the HCV care cascade in this population. This webinar will address the unique aspect of HCV and IDU and offer strategies to overcome existing limitations. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Jennifer Price

    Jennifer Price is an Associate Professor in the Department of Medicine and Division of Gastroenterology and Hepatology at the University of California, San Francisco (UCSF) and the Director of the UCSF Viral Hepatitis Center. Dr. Price leads the UCSF HCV Project Extension for Community Healthcare Outcomes (ECHO), a collaborative model of medical education and care management focused on building capacity for HCV care among primary care providers throughout Northern California. She launched UCSF’s first mobile liver clinical care unit, the DeLIVER Care Van, which aims to improve access to HCV screening and high-quality liver-related health care among medically and geographically marginalized communities. 

    Stacey Trooskin

    Stacey Trooskin, MD PhD, is the Director of Viral Hepatitis Programs at Philadelphia FIGHT Community Health Centers and Clinical Assistant Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania.  She received her MPH from Yale University School of Public Health, her medical degree from Robert Wood Johnson Medical School, and her PhD from Rutgers School of Public Health. She completed her internal medicine residency and infectious diseases fellowship at the Hospital of the University of Pennsylvania.

    Dr. Trooskin’s primary research interest focuses on health disparities and developing and evaluating innovative models of HCV testing and linkage to care. Dr. Trooskin serves at the Chief Medical Advisor to the National Viral Hepatitis Roundtable and is a member of the AASLD/IDSA HCV Guidelines Committee.  She is the Community Co-chair of the Hepatitis C Allies of Philadelphia (HepCAP) and the Principal Investigator of C Change: Philadelphia’s Plan to End Hepatitis C Among People Who Inject Drugs.

    Alain Litwin

    Dr. Alain Litwin is Vice Chair of Academics and Research and Professor of Medicine at Prisma Health, University of South Carolina School of Medicine – Greenville, and Clemson University School of Health Research where he leads a Center for Addiction and Prevention Research.  He is board certified in internal medicine and addiction medicine and has been providing medical care to people who use drugs with complex social, psychiatric and medical needs within an integrated primary care and substance use treatment program since 2000. 

    As HCV Medical Director at Albert Einstein’s Division of Substance Abuse, he developed a comprehensive on-site HCV treatment program and peer educator program to improve medical care of HCV-infected people who use drugs. As HCV Treatment Network Director at Montefiore Medical Center, he expanded patient-centered models of care at many community health centers serving thousands of HCV-infected people throughout the Bronx.  With funding from NIH, PCORI, CMS, CDC, AHRQ, Robert Wood Johnson Foundation, New York State Department of Health, New York City Department of Health, and industry, Dr. Litwin’s research has been focused on developing and studying models of addiction and medical care for people who inject drugs (PWID), and on advocating for increasing access to effective care for all PWID.  

    Dr. Litwin has worked with government and community organizations on efforts to expand access to HCV treatment and has collaborated on policy statements, clinical guidelines, treatment improvement protocols, task forces, and educational curricula with diverse stakeholders.  Dr. Litwin serves on the Executive Board for the International Network on Hepatitis in Substance Users (INHSU).

  • Management of NAFLD: Integrating Strategies from Obesity Medicine into Clinical Practice

    Contains 2 Component(s) Recorded On: 05/09/2019

    Webinar hosted by the NAFLD Special Interest Group on May 9, 2019.

    NAFLD is an increasing public health crisis. Although there are no FDA approved medications for the treatment of NAFLD, it is well established that weight loss can improve the metabolic and histologic parameters associated with NAFLD. This webinar will identify key lifestyle changes, pharmacotherapy, and the role of bariatric surgery in obesity management in patients with NAFLD. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Sonali Paul

    Sonali Paul is a transplant hepatologist and Assistant Professor of Medicine at the University of Chicago. She is also the director of the Metabolic and Fatty Liver clinic. She has an interest in non-alcoholic fatty liver disease, obesity medicine, organ allocation, health disparities, and shared decision making between patients and providers. She received an MD from Tufts University School of Medicine. She completed her internal medicine residency at Massachusetts General Hospital and returned to Tufts for her fellowship training in gastroenterology. She also earned an MS in clinical and translational science from the Sackler School of Graduate Biomedical Sciences at Tufts University. She completed an advanced hepatology fellowship at Massachusetts General Hospital in 2016 and joined the University of Chicago faculty shortly thereafter. 

    Stavra Xanthakos

    Dr. Xanthakos is a Professor of Pediatrics within the Division of Gastroenterology, Hepatology and Nutrition at Cincinnati Children’s Hospital Medical Center, with clinical and research expertise in the management of pediatric obesity and nonalcoholic fatty liver disease.  After receiving her MD degree from Duke University School of Medicine, she completed pediatric residency and fellowship training at Cincinnati Children’s.  She serves as the director of the Steatohepatitis Center, as well as the medical director of the Surgical Weight Loss Program for Teens, one of the largest adolescent bariatric surgery programs in the United States. She also collaborates with colleagues from Cardiology, Endocrinology and Psychology in a multidisciplinary behavioral weight management program for children affected by multiple obesity-related comorbid conditions.  She participates in several National Institute of Health-sponsored research consortia focused on children and adolescents with NAFLD and/or severe obesity, and also has received funding from the National Institutes of Health to investigate the outcomes of adolescents with NAFLD following bariatric surgery.

  • Liver Lesions 101

    Product not yet rated Contains 2 Component(s) Recorded On: 04/25/2019

    Webinar hosted by the Hepatology Associates Special Interest Group on April 25, 2019.

    This session will cover principles of imaging characteristics of benign and malignant hepatic lesions. Attendees will also receive an overview of the Liver Imaging Reporting and Data System (LI-RADs) for imaging findings in liver lesions and common biomarkers associated with hepatocellular carcinoma. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

  • Pediatric Liver Disorders SIG: Challenge of Fontan Associated Liver Disease

    Contains 8 Component(s) Recorded On: 11/09/2018

    AASLD's Pediatric Liver Disorders SIG: Challenge of Fontan Associated Liver Disease presented at The Liver Meeting® 2018.

    The hemodynamic changes in Fontan circulation (the palliative intervention in single ventricle physiology) confer risk of liver complications, particularly congestive hepatopathy. This program will include descriptions of the hepatopathy, the pathobiology of Fontan associated liver fibrosis, available diagnostic tools including imaging techniques and transplant-related medical decision making in the context of a failing Fontan.

    Veena Venkat

    Angela Lorts

    Elizabeth Rand

    Jonathan Dillman

    Vijay Shah

    John Magee

  • Career Development Workshop

    Contains 9 Component(s) Recorded On: 11/09/2018

    AASLD's Career Development Workshop presented at The Liver Meeting® 2018.

    This workshop will look at various training pathways for a career in hepatology. It will also describe various career opportunities in research, practice, education and industry, providing an overview of the rewards and challenges for each of these, and identify sources for research funding for fellows and junior faculty members.


    Oren K. Fix

    Oren K. Fix, MD, MSc, FAASLD is Medical Director of the Liver Transplant Program at Swedish Medical Center in Seattle. He earned his medical degree at SUNY Buffalo School of Medicine and a masters degree in Epidemiology from Boston University School of Public Health. He completed his Internal Medicine residency and Gastroenterology fellowship at Boston University and Transplant Hepatology fellowship at University of California San Francisco (UCSF). Dr. Fix was a site principal investigator in the NIH-funded Acute Liver Failure Study Group for 8 years at University of Washington and UCSF. He has published over 45 peer-reviewed manuscripts and book chapters, many on the topic of acute liver failure.

    Valentina Medici

    Emily Rothbaum Perito

    Kathleen E. Corey

    Lawrence S. Friedman

    Dr. Lawrence S. Friedman attended Princeton University and received his undergraduate and medical degrees from the Johns Hopkins School of Medicine combined BA/MD program. He did his residency training at Johns Hopkins Hospital, followed by a clinical and research fellowship in gastroenterology at Harvard Medical School and Massachusetts General Hospital. He was on the faculty of Jefferson Medical College, where he served as Vice Chairman of the Department of Medicine and a member of the Gastrointestinal Unit at Massachusetts General Hospital. He is Professor of Medicine at Harvard Medical School and Tufts University School of Medicine. Since July 1, 2003, he has been Chair of the Department of Medicine at Newton-Wellesley Hospital and Assistant Chief of Medicine at Massachusetts General Hospital.

    Mark W. Russo

    Robert Myers

  • Non-alcoholic Fatty Liver Disease SIG: Advances in Genetics and Epigenetics in NAFLD: From Pathogenesis to Personalized Medicine

    Contains 7 Component(s) Recorded On: 11/09/2018

    AASLD's Non-alcoholic Fatty Liver Disease SIG: Advances in Genetics and Epigenetics in NAFLD: From Pathogenesis to Personalized Medicine presented at The Liver Meeting® 2018.

    This program will detail recent advances in the understanding of genetic and epigenetic alterations that influence NAFLD and its progression. It will emphasize their impact on the natural history of NAFLD and variability in clinical outcomes. Details on how patient based epigenetic association studies have led to novel insights into disease pathogenesis will be outlined with an emphasis on how this may translate to new therapeutics. Finally, the role of genetics and epigenetics in the evaluation of the patient in the clinic will be addressed – with particular reference to diagnosis, prognosis and therapeutics.

    Elizabeth Speliotes

    Christopher Glass

    Derek Mann

    Luca Valenti